+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07483346

Phase Ib Study to Evaluate Safety and Dose Levels of IASO-782 for Treating Systemic Lupus Erythematosus in Adults

Led by Shanghai IASO Biotechnology Co., Ltd · Updated on 2026-08-10

20

Participants Needed

4

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and tolerability of IASO-782 in people with Systemic Lupus Erythematosus SLE through a randomized, double-blinded, placebo-controlled phase Ia clinical trial. The study focuses on subjects aged 18 to 75 years who have a confirmed diagnosis of SLE and are currently receiving standard treatment. This research aims to find the best dose range of IASO-782 for treating SLE by gradually increasing the dosage. Participants will receive IASO-782 or a placebo through intravenous infusions at doses of 4 mgkg, 6 mgkg, or 10 mgkg on days 1, 8, and 15. The infusion lasts about 90 minutes each time, with participants advised to avoid strenuous exercise 48 hours before and remain seated or semi-recumbent for 4 hours after each dose. The study uses a parallel design with randomized group assignments and quadruple masking to compare the effects of IASO-782 against placebo. During the trial, participants will be monitored for adverse events up to 25 weeks using standardized criteria. Various assessments include laboratory tests, organ function evaluations, and pregnancy tests for females of childbearing potential. Safety and tolerability will be the primary focus, with follow-up visits scheduled as needed. Participants must follow contraceptive measures throughout the study and for six months after its completion. The total study duration spans from screening to final safety evaluations.

CONDITIONS

Brief Title

IASO-782 in Systemic Lupus Erythematosus

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here